Smolen et al. assessed a multicenter, double-blinded, randomized study between February 21, 2006, and September 26, 2007, to evaluate the efficacy and safety of golimumab in RA patients who had received TNF-alpha inhibitors in the past [28]. The gene discussed is TNF; the disease is rheumatoid arthritis.